Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043550 · ClinicalTrials.gov registry record · Phase 3
Treatments for Depression: Drug Versus Psychotherapy
A Phase 3 study of Depression, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT00043550: Completed Phase 3 study of Depression, sponsored by University of Pennsylvania.
NCT00043550 is a Phase 3 study of Depression that has completed, run by University of Pennsylvania. The registered enrollment target is 156 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00043550, a Phase 3 study of Depression, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
Conditions Studied
Interventions
- DRUG Sertraline
- DRUG Venlafaxine
- BEHAVIORAL Supportive Expressive Therapy
- DRUG Pill Placebo
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043550
The ClinicalTrials.gov registry entry for NCT00043550 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Sertraline is the first listed.
NCT00043550 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00043550 about?
NCT00043550 is a clinical study titled "Treatments for Depression: Drug Versus Psychotherapy". This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
What is the current status of trial NCT00043550?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2001-11. Estimated completion is 2009-06.
What conditions does trial NCT00043550 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00043550?
The interventions under investigation include: Sertraline (DRUG), Venlafaxine (DRUG), Supportive Expressive Therapy (BEHAVIORAL), Pill Placebo (DRUG).
Who is sponsoring clinical trial NCT00043550?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043550 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.